Video

Evolving Treatment Landscape of Renal Cell Carcinoma

Transcript:

Related Videos
Viktor Grünwald, MD, PhD
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Sumanta Kumar Pal, MD, FASCO,
Kohei Shitara, MD
Kian-Huat Lim, MD, PhD
Benjamin Garmezy, MD
Kathryn Beckermann, MD, PhD
Robert Wang, MD, of Fox Chase Cancer Center
Jaime R. Merchán, MD
Related Content
Sumanta Kumar Pal, MD
June 1st 2024

DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Kelly N. Fitzgerald, MD
May 29th 2024

Nivolumab/Cabozantinib Combination Displays Activity in Non-Clear Cell RCC

Neal Shore, MD, FACS
January 26th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

Eliezer Van Allen, MD, chief, Division of Population Sciences, physician, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
May 21st 2024

Addressing Research Into the Association Between Tumor Mutations and Responses in RCC

Renal Cell Carcinoma
May 21st 2024

TIBs Linked With Poor Outcomes With Anti–PD-1 Therapy Plus Axitinib in Metastatic ccRCC